Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells

Scientific Reports

Volumn 5, Issue 1, 2015, Pages

  Cao, Wei ^a   Liu, Ying ^a,b   Zhang, Ran ^a   Zhang, Bo ^c   Wang, Teng ^a,d   Zhu, Xianbing ^a   Mei, Lin ^a   Chen, Hongbo ^a   Zhang, Hongling ^a   Ming, Pinghong ^e   Huang, Laiqiang ^a,d  

^a TSINGHUA UNIVERSITY   (China)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

^c INSTITUTE OF BIOPHYSICS   (China)

^d Tsinghua University   (China)

^e ZHUHAI PEOPLE S HOSPITAL ZHUHAI HOSPITAL AFFILIATED WITH JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; HARRINGTONINE DERIVATIVE; HOMOHARRINGTONINE; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; JAK1 PROTEIN, HUMAN; JANUS KINASE 1; QUINAZOLINE DERIVATIVE; STAT3 PROTEIN; TAXOID;

ANIMAL; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; LUNG NEOPLASMS; MALE; METABOLISM; MITOCHONDRION; MOUSE; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HARRINGTONINES; HUMANS; INTERLEUKIN-6; JANUS KINASE 1; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MITOCHONDRIA; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TAXOIDS; TRANSPLANTATION, HETEROLOGOUS;

EID: 85018193045     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/SREP08477     Document Type: Article

References (62)

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA. Cancer J. Clin. 64, 9–29 (2014).
2. Ellison, L. F. & Gibbons, L. Five-year relative survival from prostate, breast, colorectal and lung cancer. Heal. Rep 13, 23–34 (2001).
3. Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94, 153–156 (2001).
4. Scott, A. M., Wolchok, J. D. & Old, L. J. Antibody therapy of cancer. Nat Rev Cancer 12, 278–287 (2012).
5. Maemondo, M. et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380–2388 (2010).
6. Carey, K. D. et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 66, 8163–8171 (2006).
7. Engelman, J. A. & Jänne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer. Clin. Cancer Res. 14, 2895–2899 (2008).
8. Yun, C.-H. et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. 105, 2070–2075 (2008).
9. Yao, Z. et al. TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc. Natl. Acad. Sci. 107, 15535–15540 (2010).
10. Garassino, M. C. & Torri, V. Afatinib for lung cancer: let there be light? Lancet Oncol. 15, 133–134 (2014).
11. Brzezniak, C., Carter, C. A. & Giaccone, G. Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. Expert Opin. Pharmacother. 14, 247–253 (2013).
12. Kim, S. M. et al. Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation. Mol. Cancer Ther. 11, 2254–2264 (2012).
13. Schindler, C. & Darnell Jr., J. E. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem. 64, 621–652 (1995).
14. Boudny, V. & Kovarik, J. JAK/STAT signaling pathways and cancer. Janus kinases/signal transducers and activators of transcription. Neoplasma 49, 349–355 (2001).
15. Gouilleux-Gruart, V. et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 87, 1692–1697 (1996).
16. Takemoto, S. et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/ STAT proteins. Proc. Natl. Acad. Sci. 94, 13897–13902 (1997).
17. Catlett-Falcone, R. et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105–115 (1999).
18. Grivennikov, S. I. & Karin, M. Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21, 11–19 (2010).
19. Matsumoto, S. et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble–IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J. Immunol. 184, 1543–1551 (2010).
20. Bollrath, J. et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15, 91–102 (2009).
21. Hong, D. S., Angelo, L. S. & Kurzrock, R. Interleukin-6 and its receptor in cancer. Cancer 110, 1911–1928 (2007).
22. Jones, S. A., Scheller, J. & Rose-John, S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121, 3375–3383 (2011).
23. Lesina, M. et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19, 456–469 (2011).
24. Chen, G. K., Sale, S., Tan, T., Ermoian, R. P. & Sikic, B. I. CCAAT/Enhancer-Binding Protein β (Nuclear Factor for Interleukin 6) Transactivates the Human MDR1 Gene by Interaction with an Inverted CCAAT Box in Human Cancer Cells. Mol. Pharmacol. 65, 906–916 (2004).
25. Gao, S. P. et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 117, 3846–3856 (2007).
26. Chiu, H.-C. et al. Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells. Biochem. Pharmacol. 81, 1263–1270 (2011).
27. Song, L., Rawal, B., Nemeth, J. A. & Haura, E. B. JAK1 Activates STAT3 Activity in Non-Small–Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling. Mol. Cancer Ther. 10, 481–494 (2011).
28. Kantarjian, H. M. et al. Homoharringtonine. Cancer 92, 1591–1605 (2001).
29. Huang, C. C. et al. Cytotoxicity and sister chromatid exchanges induced in vitro by six anticancer drugs developed in the People’s Republic of China. J. Natl. Cancer Inst. 71, 841–847 (1983).
30. Feldman, E. J., Seiter, K. P., Ahmed, T., Baskind, P. & Arlin, Z. A. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia 10, 40–42 (1996).
31. Kantarjian, H. M. et al. Phase II study of low‐dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 63, 813–817 (1989).
32. Quintás‐Cardama, A. et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109, 248–255 (2007).
33. Chen, R. et al. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 117, 156–164 (2011).
34. Gürel, G., Blaha, G., Moore, P. B. & Steitz, T. A. U2504 Determines the Species Specificity of the A-Site Cleft Antibiotics:: The Structures of Tiamulin, Homoharringtonine, and Bruceantin Bound to the Ribosome. J. Mol. Biol. 389, 146–156 (2009).
35. Efferth, T., Sauerbrey, A., Halatsch, M. E., Ross, D. D. & Gebhart, E. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines. Naunyn. Schmiedebergs. Arch. Pharmacol. 367, 56–67 (2003).
36. Meng, H., Yang, C., Jin, J., Zhou, Y. & Qian, W. Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Leuk. Lymphoma 49, 1954–1962 (2008).
37. Giorgi, C. et al. Mitochondrial Ca(2+) and apoptosis. Cell Calcium 52, 36–43 (2012).
38. Soboloff, J., Rothberg, B. S., Madesh, M. & Gill, D. L. STIM proteins: dynamic calcium signal transducers. Nat. Rev. Mol. Cell Biol. 13, 549–565 (2012).
39. Akgul, C., Turner, P. C., White, M. R. H. & Edwards, S. W. Functional analysis of the human MCL-1 gene. Cell. Mol. Life Sci. C. 57, 684–691 (2000).
40. Harada, D., Takigawa, N. & Kiura, K. The Role of STAT3 in Non-Small Cell Lung Cancer. Cancers (Basel). 6, 708–722 (2014).
41. Looyenga, B. D. et al. STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma. PLoS One 7, e30820 (2012).
42. Bromberg, J. F. et al. Stat3 as an oncogene. Cell 98, 295–303 (1999).
43. Hirano, T., Ishihara, K. & Hibi, M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2, 2548–2556 (2000).
44. Bihl, M. et al. Proliferation of Human Non–Small-Cell Lung Cancer Cell Lines: Role of Interleukin-6. Am. J. Respir. Cell Mol. Biol. 19, 606–612 (1998).
45. Von Minckwitz, G. Docetaxel/anthracycline combinations for breast cancer treatment. Expert Opin. Pharmacother. 8, 485–495 (2007).
46. Montero, A., Fossella, F., Hortobagyi, G. & Valero, V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 6, 229–239 (2005).
47. Chou, T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440–446 (2010).
48. Scott, H. R., McMillan, D. C., Crilly, A., McArdle, C. S. & Milroy, R. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br. J. Cancer 73, 1560 (1996).
49. Liu, Y., Li, P.-K., Li, C. & Lin, J. Inhibition of STAT3 Signaling Blocks the Anti-apoptotic Activity of IL-6 in Human Liver Cancer Cells. J. Biol. Chem. 285, 27429–27439 (2010).
50. Bell, D. W. et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat. Genet. 37, 1315–1316 (2005).
51. Godin-Heymann, N. et al. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res. 67, 7319–7326 (2007).
52. Bunn, P. A. & Kelly, K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. cancer Res. 4, 1087–1100 (1998).
53. Donaldson, K. L., Goolsby, G. L., Kiener, P. A. & Wahl, A. F. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ. 5, 1041–1050 (1994).
54. Wang, L. G., Liu, X. M., Kreis, W. & Budman, D. R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol. 44, 355–361 (1999).
55. Soule, H. D. et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 50, 6075–6086 (1990).
56. Hillion, J. et al. The High-Mobility Group A1a/Signal Transducer and Activator of Transcription-3 Axis: An Achilles Heel for Hematopoietic Malignancies? Cancer Res. 68, 10121–10127 (2008).
57. Lois, C., Hong, E. J., Pease, S., Brown, E. J. & Baltimore, D. Germline Transmission and Tissue-Specific Expression of Transgenes Delivered by Lentiviral Vectors. Sci. 295, 868–872 (2002).
58. Yu, X.-J. et al. Gambogenic acid induces G1 arrest via GSK3β-dependent cyclin D1 degradation and triggers autophagy in lung cancer cells. Cancer Lett. 322, 185–194 (2014).
59. Zhang, B. et al. Gefitinib Analogue V1801 Induces Apoptosis of T790M EGFR-Harboring Lung Cancer Cells by Up-Regulation of the BH-3 Only Protein Noxa. PLoS One 7, e48748 (2012).
60. Ma, L. et al. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS One 6, e20159 (2011).
61. Liu, Y. et al. The natural compound magnolol inhibits invasion and exhibits potential in human breast cancer therapy. Sci. Rep. 3, 3098 (2013).
62. Nakao, K. et al. The development of a bioengineered organ germ method. Nat Meth 4, 227–230 (2007).